Biogen's 2025 Profit Misses Expectations
This is a US news story, published by Yahoo Finance, that relates primarily to Biogen news.
US news
For more US news, you can click here:
more US newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsYahoo Finance news
For more news from Yahoo Finance, you can click here:
more news from Yahoo FinanceAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Biogen shares. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Biogen news, Reata Pharmaceuticals news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
Biogen stockReuters
•Health
Health
Drugmaker Biogen forecasts 2025 profit below expectations

82% Informative
Biogen stock fell 3% in pre-market trading on Wednesday .
Investors sold Biogen shares in 2024 as a slow US launch of Leqembi , the Alzheimer's disease drug it sells with Japan 's Eisai , exacerbated worries of slowing sales growth.
Biogen expects 2025 revenue to decline by a mid-single digit percentage, excluding the impact of currency fluctuations.
VR Score
93
Informative language
98
Neutral language
89
Article tone
formal
Language
English
Language complexity
48
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links